I
Iterum Therapeutics
Pharmaceutical developing differentiated anti-infectives
About Iterum Therapeutics
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company focused on developing innovative anti-infective treatments. The company primarily targets multi-drug resistant (MDR) pathogens, which are bacteria that have become resistant to multiple antibiotics, posing a significant global health threat. Iterum's core product is a novel anti-infective compound that has shown potent activity against a wide range of gram-negative, gram-positive, and anaerobic bacteria in laboratory tests.
The company operates in the pharmaceutical and biotechnology market, serving healthcare providers, hospitals, and patients who are affected by serious and life-threatening infections. Iterum's business model revolves around the research, development, and commercialization of its proprietary anti-infective compounds. Revenue is generated through the sale of these pharmaceutical products, as well as potential partnerships and licensing agreements with other healthcare companies.
Iterum Therapeutics aims to address the urgent need for new antibiotics in the face of rising antibiotic resistance. By focusing on differentiated anti-infectives, the company seeks to improve patient outcomes and provide effective treatment options where existing antibiotics have failed.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2018
News
Open roles
Iterum Therapeutics in the Dublin ecosystem
The Iterum Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Canaan
New Leaf Venture Partners
Sofinnova Partners
Frazier Healthcare Partners
Arix Bioscience
Pivotal Life Sciences- BCBay City Capital
Advent Life Sciences
Domain Associates
Sofinnova Investments
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Iterum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Iterum Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


